Original Research| Volume 183, P98-108, April 2023

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

Published:January 10, 2023DOI:


      • Capmatinib is indicated for advanced NSCLC with MET exon 14 skipping alterations.
      • We present the analysis of the patient-reported outcomes from the GEOMETRY mono-1 trial.
      • Patient-reported outcomes included the EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-5L.
      • Capmatinib led to clinically meaningful improvements in cough and preserved QoL.
      • Benefit was observed for both treatment-naïve and previously treated patients.



      Capmatinib, a MET inhibitor, showed substantial antitumour activity with manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC) in the GEOMETRY mono-1 study. We report patient-reported outcomes (PROs) from this study.


      Enrolled treatment-naïve (1L) or pre-treated (2L+) patients with aNSCLC with a METex14-skipping mutation received 400 mg capmatinib twice daily during 21-day treatment cycles. PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 symptoms, and EQ-5D-5L visual analogue scale (VAS) questionnaires.


      As of 6 January 2020, 27/28 1L and 65/69 2L+ patients had completed PROs at baseline; compliance rates remained >70%. Cough improved early, with meaningful improvements (≥10-point change from baseline) observed throughout cycles (mean change from baseline [SD] by week 7: 1L −13.0 [39.9], 2L+ −8.2 [28.4]; week 43: 1L −28.2 [26.7], 2L+ −10.5 [27.3]). QoL, assessed by GHS/QoL and VAS, improved by week 7 in 1L and 2L+ patients, with improvements generally sustained over time. Median time to definitive deterioration (TTDD) in GHS/QoL was 16.6 months (95% CI: 9.7, not estimable [NE]) in 1L and 12.4 months (95% CI: 4.2, 19.4) in 2L+ patients. Median TTDD for dyspnoea was 19.4 months (95% CI: 12.4, NE) and 22.1 months (95% CI: 9.9, NE) for 1L and 2L+ patients, respectively, and NE for cough and chest pain.


      Capmatinib was associated with clinically meaningful improvements in cough and preserved QoL, further supporting its use in patients with METex14-mutated aNSCLC.

      Trial registration registry number: NCT02414139.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Walters S.
        • Maringe C.
        • Coleman M.P.
        • et al.
        Module 1 Working Group. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007.
        Thorax. 2013; 68: 551-564
        • Denton E.J.
        • Hart D.
        • Wainer Z.
        • et al.
        Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre.
        Intern Med J. 2016; 46: 946-954
        • Barbera L.
        • Seow H.
        • Howell D.
        • et al.
        Symptom burden and performance status in a population-based cohort of ambulatory cancer patients.
        Cancer. 2010; 116: 5767-5776
        • Sung M.R.
        • Patel M.V.
        • Djalalov S.
        • et al.
        Evolution of symptom burden of advanced lung cancer over a decade.
        Clin Lung Cancer. 2017; 18 (e6): 274-280
        • Andersen B.L.
        • Valentine T.R.
        • Lo S.B.
        • et al.
        Newly diagnosed patients with advanced non-small cell lung cancer: a clinical description of those with moderate to severe depressive symptoms.
        Lung Cancer. 2019; 145: 195-204
        • Cooley M.E.
        Symptoms in adults with lung cancer. A systematic research review.
        J Pain Symptom Manag. 2000; 19: 137-153
        • Graves K.D.
        • Arnold S.M.
        • Love C.L.
        • et al.
        Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress.
        Lung Cancer. 2007; 55: 215-224
        • The Cancer Genome Atlas Research Network
        Comprehensive molecular profiling of lung adenocarcinoma.
        Nature. 2014; 511: 543-550
        • Onozato R.
        • Kosaka T.
        • Kuwano H.
        • et al.
        Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
        J Thorac Oncol. 2009; 4: 5-11
        • Tong J.H.
        • Yeung S.F.
        • Chan A.W.H.
        • et al.
        MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis.
        Clin Cancer Res. 2016; 22: 3048-3056
        • Yeung S.F.
        • Tong J.H.M.
        • Law P.P.W.
        • et al.
        Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor.
        J Thorac Oncol. 2015; 10: 1292-1300
        • Frampton G.M.
        • Ali S.M.
        • Rosenzweig M.
        • et al.
        Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
        Cancer Discov. 2015; 5: 850-859
        • Awad M.M.
        • Leonardi G.C.
        • Kravets S.
        • et al.
        Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
        Lung Cancer. 2019; 133: 96-102
        • TABRECTA
        Capmatinib US prescribing information.
        Novartis, New Jersey, USA2020
        • TEPMETKO
        Tepotinib US prescribing information.
        Merck KGaA, Rockland, USA2021
      1. Novartis. Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis. Accessed April 1, 2022.

      2. Novartis. Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC. Accessed April 1, 2022.

        • Wolf J.
        • Seto T.
        • Han J.-Y.
        • et al.
        GEOMETRY mono-1 investigators. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer.
        N Engl J Med. 2020; 383: 944-957
        • Cortot A.
        • Le X.
        • Smit E.
        • et al.
        Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review.
        Clin Lung Cancer. 2022; 23: 195-207
        • Aaronson N.K.
        • Ahmedzai S.
        • Bergman B.
        • et al.
        The European organization for research and treatment of cancer qlq-C30: a quality-of-life instrument for use in international clinical trials in Oncology.
        J Natl Cancer Inst. 1993; 85: 365-376
        • Bergman B.
        • Aaronson N.K.
        • Ahmedzai S.
        • et al.
        The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life.
        Eur J Cancer. 1994; 30A: 635-642
        • Osoba D.
        • Rodrigues G.
        • Myles J.
        • et al.
        Interpreting the significance of changes in health-related quality-of-life scores.
        J Clin Oncol. 1998; 16: 139-144
        • Herdman M.
        • Gudex C.
        • Lloyd A.
        • et al.
        Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
        Qual Life Res. 2011; 20: 1727-1736
        • Polanski J.
        • Jankowska-Polanska B.
        • Rosinczuk J.
        • et al.
        Quality of life of patients with lung cancer.
        OncoTargets Ther. 2016; 9: 1023-1028
        • Pickard S.A.
        • Neary M.P.
        • Cella D.
        Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.
        Health Qual Life Outcome. 2007; 5: 70
        • Garassino M.C.
        • Le X.
        • Kowalski D.
        • et al.
        Health-related quality of life in patients with NSCLC harboring MET exon 14 skipping treated with tepotinib.
        in: Presented at the European Society for Medical Oncology Virtual Congress. 2020 (September 19–21)
        • Cocks K.
        • King M.
        • Velikova G.
        • et al.
        Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30.
        Eur J Cancer. 2012; 48: 1713-1721
        • Cocks K.
        • King M.T.
        • Velikova G.
        • et al.
        Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire core 30.
        J Clin Oncol. 2011; 29: 89-96